293 related articles for article (PubMed ID: 15742436)
21. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction.
Bijl M; Bootsma H; Van Der Geld Y; Limburg PC; Kallenberg CG; Van Rijswijk MH
Ann Rheum Dis; 2004 Jul; 63(7):831-5. PubMed ID: 15194579
[TBL] [Abstract][Full Text] [Related]
22. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics.
Omdal R; Mellgren SI; Koldingsnes W; Jacobsen EA; Husby G
J Rheumatol; 2002 Mar; 29(3):482-6. PubMed ID: 11908560
[TBL] [Abstract][Full Text] [Related]
23. Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus?
Rezaieyazdi Z; Sahebari M; Hatef MR; Abbasi B; Rafatpanah H; Afshari JT; Esmaily H
Lupus; 2011 Dec; 20(14):1494-500. PubMed ID: 21993388
[TBL] [Abstract][Full Text] [Related]
24. C-reactive protein in sera from patients with systemic lupus erythematosus.
Morrow WJ; Isenberg DA; Parry HF; Snaith ML
J Rheumatol; 1981; 8(4):599-604. PubMed ID: 7299761
[TBL] [Abstract][Full Text] [Related]
25. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
[TBL] [Abstract][Full Text] [Related]
26. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease.
Brugos B; Kiss E; Dul C; Gubisch W; Szegedi G; Sipka S; Zeher M
Hum Immunol; 2010 Sep; 71(9):874-7. PubMed ID: 20538031
[TBL] [Abstract][Full Text] [Related]
27. C-reactive protein and cognitive deficits in systemic lupus erythematosus.
Shucard JL; Gaines JJ; Ambrus J; Shucard DW
Cogn Behav Neurol; 2007 Mar; 20(1):31-7. PubMed ID: 17356342
[TBL] [Abstract][Full Text] [Related]
28. [The importance of determination of interleukin-10 in the blood of patients with systemic lupus erythematosus].
Scudla V; Horák P; Faltýnek L; Pospísil Z; Budíková M; Hermanová Z
Cas Lek Cesk; 1998 Jan; 137(2):44-7. PubMed ID: 9511265
[TBL] [Abstract][Full Text] [Related]
29. Elevation of serum CXCL13 in SLE as well as in sepsis.
Schiffer L; Kielstein JT; Haubitz M; Lührs H; Witte T; Haller H; Kümpers P; Schiffer M
Lupus; 2011 Apr; 20(5):507-11. PubMed ID: 21078761
[TBL] [Abstract][Full Text] [Related]
30. IL-18 is involved in vascular injury in end-stage renal disease patients.
Porazko T; Kúzniar J; Kusztal M; Kúzniar TJ; Weyde W; Kuriata-Kordek M; Klinger M
Nephrol Dial Transplant; 2009 Feb; 24(2):589-96. PubMed ID: 18775894
[TBL] [Abstract][Full Text] [Related]
31. Proinflammatory interferon-gamma--inducing monokines (interleukin-12, interleukin-18, interleukin-15)--serum profile in patients with systemic lupus erythematosus.
Robak E; Robak T; Wozniacka A; Zak-Prelich M; Sysa-Jedrzejowska A; Stepien H
Eur Cytokine Netw; 2002; 13(3):364-8. PubMed ID: 12231481
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
[TBL] [Abstract][Full Text] [Related]
33. Complement degradation product C3d in urine: marker of lupus nephritis.
Negi VS; Aggarwal A; Dayal R; Naik S; Misra R
J Rheumatol; 2000 Feb; 27(2):380-3. PubMed ID: 10685801
[TBL] [Abstract][Full Text] [Related]
34. Unresponsiveness of C-reactive protein in the non-infectious inflammation of systemic lupus erythematosus is associated with interleukin 6.
Suh CH; Chun HY; Ye YM; Park HS
Clin Immunol; 2006 Jun; 119(3):291-6. PubMed ID: 16406714
[TBL] [Abstract][Full Text] [Related]
35. Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response.
Lacki JK; Leszczynski P; Kelemen J; Müller W; Mackiewicz SH
J Med; 1997; 28(1-2):99-107. PubMed ID: 9249616
[TBL] [Abstract][Full Text] [Related]
36. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus.
Robak E; Sysa-Jedrzejowska A; Stepień H; Robak T
Eur Cytokine Netw; 1997 Sep; 8(3):281-6. PubMed ID: 9346362
[TBL] [Abstract][Full Text] [Related]
37. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus.
Sabry AA; Elbasyouni SR; Kalil AM; Abdel-Rahim M; Mohsen T; Sleem A
Nephrology (Carlton); 2006 Aug; 11(4):329-35. PubMed ID: 16889573
[TBL] [Abstract][Full Text] [Related]
38. Erosive arthritis in systemic lupus erythematosus is associated with high serum C-reactive protein and anti-cyclic citrullinated peptide antibodies.
Amezcua-Guerra LM; Márquez-Velasco R; Bojalil R
Inflamm Res; 2008 Dec; 57(12):555-7. PubMed ID: 19109734
[TBL] [Abstract][Full Text] [Related]
39. Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?
Enocsson H; Sjöwall C; Skogh T; Eloranta ML; Rönnblom L; Wetterö J
Arthritis Rheum; 2009 Dec; 60(12):3755-60. PubMed ID: 19950271
[TBL] [Abstract][Full Text] [Related]
40. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
